Gold Fields Limited (NYSE:GFI)
Gold Fields Limited (NYSE:GFI) represented a move of -3.27 percent or $0.08 per share and closed its previous day trading session at $2.66. 5.22 Million Shares were traded in the last trading session with an Average Volume of 4.93 Million Shares. The stock currently has a Market Capitalization of 2.25 Billion.
Gold Fields Limited is one of the world’s largest unhedged gold producers with operating mines in South Africa, Ghana, and Australia.
The stock traded between $2.20 and $4.54 over 1-Year time period showing its price to sales ratio of 0.8. Gold Fields Limited (NYSE:GFI) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $3.72 and 200-Day Simple Moving Average of $-23.45. Its Price to Free Cash Flow is 7.9 and Price to Book of 0.8.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
Exact Sciences Corporation (NASDAQ:EXAS)
In the last trading session, Exact Sciences Corporation (NASDAQ:EXAS) added its value by 10.33% closing at the price of $71.05. The stock currently has market capitalization of 8.57 Billion, with average volume of 2.3 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Exact Sciences Corporation (NASDAQ:EXAS) is showing beta of 1.35. This particular value of beta suggests that Exact Sciences Corporation (NASDAQ:EXAS) has historically moved 135% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Exact Sciences Corporation (NASDAQ:EXAS) is at $-2.07.
The stock currently has RSI of 55.1. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Exact Sciences Corporation (NASDAQ:EXAS) topped its 52-week high price of $81.22 on 09/25/18 and 52-Week Low Price of $37.36 on 04/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.26% and monthly volatility of 6.02% respectively.